## Isolation and Characterization of Brachystemidines A-E, Novel Alkaloids from Brachystemma calycinum

Yong-Xian Cheng,<sup>†</sup> Jun Zhou,<sup>\*,†</sup> Ning-Hua Tan,<sup>†</sup> Rong-Wei Teng,<sup>†</sup> Yang Lu,<sup>‡</sup> Cheng Wang,<sup>‡</sup> and Qi-Tai Zheng<sup>‡</sup>

Laboratory of Phytochemistry, Kunming Institute of Botany, The Chinese Academy of Sciences, Kunming 650204, People's Republic of China, and The Institute of Materia Medica, The Chinese Academy of Medical Science, Beijing 100050, People's Republic of China

Received June 29, 2001

Five novel alkaloids, brachystemidines A-E (1-5), were isolated from the roots of *Brachystemma* calycinum. Their structures were established by spectral data, especially by 1D and 2D NMR techniques. The crystal structure of brachystemidine D was determined via X-ray diffraction analysis.

Brachystemma calycinum D. Don (Caryophyllaceae) is the only member of the genus Brachystemma. It is sporadically distributed in the southwest of China.<sup>1</sup> In China it has been used as a folk medicine for rheumatism, limb numbness, impotence, and edema of the feet.<sup>2</sup> Our chemical investigation on *B. calycinum* has led to the isolation of five novel alkaloids (1-5) named brachystemidines A-E.

Brachystemidine A (1) was obtained as a white solid from the EtOAc extract of the roots of *B. calycinum*. The molecular formula,  $C_{15}H_{18}N_2O_5$ , which indicated eight unsaturations, was deduced from HREIMS at m/z 306.1238 (calcd. 306.1218) and from the <sup>13</sup>C NMR and DEPT spectra. The <sup>1</sup>H and <sup>13</sup>C NMR data (Table 1), including <sup>1</sup>H-<sup>1</sup>H COSY, HMQC, and HMBC (Table 1) spectra, suggested that **1** was an alkaloid consisting of three ring systems, a pyrrole, a dihydrofuran, and a pyrrolidone residue. The 2-substituted pyrrole fragment was deduced from comparison of <sup>13</sup>C NMR spectral data with 3-furfuryl pyrrole-2carboxylate.<sup>3</sup> The  ${}^{1}H^{-1}H$  cross-peaks between  $H_{a}$ -3" ( $\delta$ 2.17, m) and H<sub>b</sub>-4" ( $\delta$  1.93, m), between H<sub>b</sub>-3" ( $\delta$  2.43, m) and  $H_a$ -4" ( $\delta$  1.97, m), and between  $H_a$ -4" ( $\delta$  1.97, m) and H-5" ( $\delta$  4.74, m), together with H-3", H<sub>b</sub>-4", and H-5", all correlating with the amide carbonyl group ( $\delta$  175.1) in the HMBC spectrum, indicated the presence of a substituted pyrrolidone. Protons ( $\delta$  3.11, 3H, s) correlating with C-5" ( $\delta$  87.7) in the HMBC spectrum implied that one OMe was linked with C-5". The presence of a substituted 2,5dihydrofuran moiety was indicated in the HMBC spectrum by correlations of  $H_{b}$ -5' ( $\delta$  4.73) with C-2' ( $\delta$  86.5), C-3' ( $\delta$ 127.4), and C-4' ( $\delta$  134.3). The signals resonating at  $\delta$  86.5 and 74.5 were indicative of oxygen-bearing atoms. That one CH<sub>2</sub> bearing an oxygen atom (H-6') was linked to the 4'position of the dihydrofuran ring and was supported by its HMBC correlations with C-3' ( $\delta$  127.4) and C-4' ( $\delta$  134.3), in addition to C-6 ( $\delta$  160.0). The linkage of the pyrrolidone and dihydrofuran residue was accomplished by observations of HMBC correlations between H-2' (& 6.38) and C-5" ( $\delta$  87.7) and between H-5" ( $\delta$  4.74) and C-2' ( $\delta$  86.5). A carbonyl ester bond was reasonable for connecting the dihydrofuran and pyrrole. The obvious <sup>1</sup>H–<sup>1</sup>H cross-peaks of  $H_{b}$ -5' ( $\delta$  4.73) and H-2' ( $\delta$  6.38) indicated zigzag coupling. Such a phenomenon required the two protons to be positioned in one plane, and hence, the five-membered ring should adopt an envelope conformation. Thus, the structure of brachystemidine A was assigned as **1**.

The EIMS and <sup>1</sup>H and <sup>13</sup>C NMR spectra (Tables 2 and 3) of **2** were surprisingly similar to those of **1**, although they were recorded in different solvents. However, their TLC behavior was different in three different solvent systems, implying that **2** was isomeric with **1**. The clear HMBC correlations of  $H_a$ -6' ( $\delta$  4.73) and  $H_b$ -6' ( $\delta$  4.71) both with C-2' ( $\delta$  87.5) in **2** and their absence in **1** suggested that 2 was the 3'-positional isomer of 1. Likewise, the conformation of the substituted 2',5'-dihydrofuran was assumed via a zigzag coupling of  $H_b$ -5' ( $\delta$  4.66) and H-2' ( $\delta$ 6.60). Hence, the structure of brachystemidine B was assigned as 2.

The similarities of the <sup>1</sup>H and <sup>13</sup>C NMR data (Tables 2 and 3) of **3** with **1** and **2** suggested that **3** was a derivative of 1 or 2. The EIMS of 3 displayed 16 amu more than 1 or 2, besides a significant downfield shift of C-3" which appeared at  $\delta$  68.6 in **3** rather than at  $\delta$  29.3 as in **2** or at  $\delta$  28.8 as in 1; this suggested a hydroxyl group was located at C-3" in **3**. The HMBC correlations of H-6' ( $\delta$  4.76 and 4.97) with C-2' ( $\delta$  88.3) indicated that the 3'-position of **3** was substituted. The conformation of the 2',5'-dihydrofuran was established through the  $^{1}H^{-1}H$  interactions of H-2' ( $\delta$ 6.44) and  $H_{b}$ -5' ( $\delta$  4.70), which were positioned in the 'W'form. Hence, brachystemidine C was assigned as 3.

The EIMS, <sup>1</sup>H, <sup>13</sup>C NMR, and DEPT spectra (Table 1) indicated that the planar structure of 4 was an 5"-OHsubstituted derivative of 1 or 2. The 5"-OH substituent of **4** was evidenced in the <sup>13</sup>C NMR and EIMS spectra. The absence of an OMe signal and a mass of 14 amu less than that of 1 or 2 indicated that the substituent at C-5" in 4 was an OH rather than an OMe. This change resulted in an upfield shift of the C-5" resonance from  $\delta$  87.7 in 1 to  $\delta$ 80.4 in **4**. The clear interaction of  $H_b$ -6' ( $\delta$  5.10) with C-2' ( $\delta$  87.1) in the HMBC spectrum (Table 1) suggested that the 3'-position of **4** was the point of attachment. In addition, the  ${}^{1}H^{-1}H$  correlations of  $H_{b}$ -5' ( $\delta$  4.76) and H-2' ( $\delta$  6.61) showed the typical zigzag coupling. This assumption was verified by X-ray diffraction analysis (Figure 1), which also indicated that the 5"-OH had an  $\alpha\mbox{-}orientation.$ 

The EIMS and <sup>1</sup>H and <sup>13</sup> C NMR spectra (Tables 2 and 3) of **5** were similar to those of **1**-**4**. The main difference in the <sup>13</sup>C NMR spectra of **5** compared with **4** was at the pyrrolidone ring. Another carbon signal ( $\delta$  68.1) bearing an oxygen atom was observed. The <sup>1</sup>H-<sup>1</sup>H COSY suggested the presence of X–CH–CH<sub>2</sub>–CH–X (C-3"–C–C-5"). The EIMS gave a molecular ion peak at m/z 308, which was 16 amu more than that of 4. The above data indicated that the planar structure of 5 was closely related to 3"hydroxybrachystemidine D. A zigzag coupling of H-2' ( $\delta$ 

10.1021/np010330c CCC: \$22.00 © 2002 American Chemical Society and American Society of Pharmacognosy Published on Web 04/11/2002

<sup>&</sup>lt;sup>‡</sup> Chinese Academy of Medical Science.

	<b>1</b> <sup><i>a</i></sup>			<b>4</b> <sup>b</sup>		
no.	<sup>1</sup> H	<sup>13</sup> C	HMBC	<sup>1</sup> H	<sup>13</sup> C	HMBC
NH	11.86, br s			10.12, br s		
2		121.5 s			121.8 s	
3	6.62, br s	115.6 d		6.94, m	116.5 d	
4	6.16, br d (2.0)	109.7 d		6.21, dd (6.0, 2.4)	110.6 d	2
5	7.02, d (4.4)	124.4 d		6.94, m	123.8 d	
6		160.0 s			160.7 s	
2′	6.38, br d (3.6)	86.5 d	3', 4'	6.61, t (2.4)	87.1 d	3', 4', 2", 5"
3′	6.29, br s	127.4 d	6'		134.9 s	
4'		134.3 s		5.97, d (1.2)	126.4 d	2′
4' 5'	4.53 (1H, br d, 13.6, a);	74.5 t	2', 4' 2', 3', 4'	4.59 (1H, br d, 13.6, a);	74.9 t	2', 3', 4'
	4.73 (1H, br d, 13.6, b)			4.76 (1H, dd, 13.6, 2.2, b)		
6'	4.76 (1H, d, 13.6, a);	58.7 t	3', 4', 6	4.67 (1H, br d, 14.8, a);	59.7 t	6, 2', 3', 4'
	4.59 (1H, d, 13.6, b)			5.10 (1H, d, 14.8, b)		
2″		175.1 s		• • • • •	176.2 s	
3″	2.17 (1H, m, a);	28.8 t	2", 4", 5" 2", 4"	2.66, (2H, m)	29.3 t	2", 5"
	2.43 (1H, m, b)					
4″	1.97 (1H, m, a);	24.4 t	3" 2", 5"	1.89 (1H, m, a);	28.7 t	2", 5"
	1.93 (1H, m, b)			2.25 (1H, m, b)		
5" OH-5" OMe	4.74, m; 3.11, s	87.7 d 53.9 q	2', 2'' 5''	5.37, br s; 4.53, br s	80.4 d	2', 2''

Table 1. <sup>1</sup>H, <sup>13</sup>C NMR and HMBC Data for Compounds 1 and 4


<sup>*a*</sup> Spectra were recorded in DMSO- $d_6$  (400 MHz for  $\delta_H$  and 100.6 MHz for  $\delta_C$ ). <sup>*b*</sup> Spectra were recorded in CDCl<sub>3</sub> (400 MHz for  $\delta_H$  and 100.6 MHz for  $\delta_C$ ).

Table 2. <sup>1</sup>H NMR Data for Compounds 2, 3, and 5 (400 MHz)<sup>a</sup>

$^{1}\mathrm{H}$	2	3	5
NH	9.52, br s	9.74, br s	10.50, br s
3	6.92, br d (2.0)	6.90, br d (2.4)	6.97, m
4	6.24, m	6.24, dd (3.2, 1.8)	6.23, dd (2.5, 1.5)
5	6.96, dd (3.8, 2.5)	6.97, br d (1.0)	6.97, m
2'	6.60, br d (4.6)	6.44, d (5.0)	6.55, t (2.0)
4'	6.24, m	6.25, m	6.09, t (1.5)
5′	4.55 (1H, dd, 12.8, 3.2 a);	4.58 (1H, br d, 13.4, a);	4.64 (1H, br d, 14.0, a);
	4.66 (1H, dd, 12.8, 2.2, b)	4.70 (1H, dd, 13.4, 5.2, b)	4.74 (1H, dd, 14.0, 1.5, b)
6′	4.73 (1H, dd, 13.6, 2.6, a);	4.76 (1H, d, 13.6, a);	4.69 (1H, d, 14.0, a);
	4.71 (1H, d, 13.6, b)	4.97 (1H, d, 13.6, b)	5.02 (1H, d, 14.0, b)
3″	2.25 (1H, m, a);	4.05, dd (9.0, 5.3)	4.67, m
	2.57 (1H, m, b)		
4″	1.96 (1H, m, a);	1.87, (1H, m, a);	2.10, (1H, m, a);
	1.99 (1H, m, b)	2.41, (1H, m, b)	2.39, (1H, m, b)
5" OH-3" OH-5"	4.97, m	5.00, dd (6.6, 3.6); 3.61, br s	5.29, d (6.5)
OMe	3.11, s	3.22, s	

<sup>a</sup> Compounds 2, 3 and 5 were all measured in CDCl<sub>3</sub>.

6.55) and  $H_b\text{-}5'$  ( $\delta$  4.74) in the  $^1H\text{--}^1H$  COSY spectrum implied that these two protons were coplanar. Thus, the structure of brachystemidine E was assigned as 5.



**3** R<sub>1</sub>=CH<sub>3</sub>O, R<sub>2</sub>=OH **5** R<sub>1</sub>= R<sub>2</sub>=OH

It is noted that alkaloids of this type are seldom found in nature. To our knowledge, the only previous example is **Table 3.**  $^{13}$  C NMR Data for Compounds **2**, **3**, and **5** (100.6 MHz)<sup>a</sup>

<sup>13</sup> C	2	3	5
2	122.1 s	121.9 s	121.5 s
3	116.0 d	116.0 d	116.5 d
4	110.6 d	110.6 d	110.2 d
5	123.5 d	123.7 d	124.0 d
6	160.2 s	160.8 s	160.9 s
2′	87.5 d	88.3 d	87.1 d
3′	132.0 s	131.5 s	133.9 s
4'	129.7 d	130.7 d	127.4 d
5′	74.4 t	74.8 t	75.0 t
6′	58.8 t	58.7 t	59.3 t
2″	175.9 s	174.8 s	176.7 s
3″	29.3 t	68.6 d	68.1 d
4″	24.1t	32.6 t	38.5 t
5″	88.1 d	86.2 d	77.0 d
OMe-5"	52.1 q	51.8 q	

<sup>*a*</sup> Compound **2**, **3**, and **5** were all measured in CDCl<sub>3</sub>.

3-furfuryl pyrrole-2-carboxylate, isolated from *Pseudostellaria heterophylla* (Caryophyllaceae)<sup>3</sup> as a natural product.

## **Experimental Section**

**General Experimental Procedures.** Melting points were determined with a XRC-1 apparatus and are uncorrected. Optical rotations were determined on a JASCO-20C digital polarimeter. Routine <sup>1</sup>H (400 MHz) and <sup>13</sup>C NMR (100.6 MHz)




Figure 1. X-ray structure of 4.

spectra were recorded on a Bruker AM-400 spectrometer with TMS as internal standard. 2D NMR spectra were measured on a DRX-500 spectrometer. MS analyses were carried out on a VG Auto Spec-3000 spectrometer.

**Plant Material.** The roots (13 kg) of *B. calycinum* were collected in Xishuangbanna of Yunnan Province of China at the end of March, 1999. A voucher specimen (No. 1) was deposited in the herbarium of Kunming Institute of Botany, The Chinese Academy of Sciences.

Extraction and Isolation. Powdered, dried roots (13 kg) of *B. calycinum* were extracted with 95% EtOH (3  $\times$  50 L) under reflux three times (3 h, 1.5 h, and 1.5 h). After concentration of the combined extracts under reduced pressure, the residues were diluted with H<sub>2</sub>O and then partitioned with petroleum ether (60-90 °C), EtOAc, and n-BuOH (presaturated with water), respectively. The ethyl acetate portion (50.0 g) was subjected to CC over silica gel (2300 g, 200-300 mesh) eluting with CHCl<sub>3</sub>-MeOH (17:1 to 8:2, 7 L each eluent) to give five fractions. Fraction 2 was subjected to flash chromatography eluting with petroleum ether-Me<sub>2</sub>CO (10:1-5:1) and CHCl<sub>3</sub>-Me<sub>2</sub>CO (10:1-5:1) to afford subfractions 2.1 and 2.2. Fraction 2.1 was chromatographed on Si gel by VLC with CHCl<sub>3</sub>-EtOAc (5:1-1:1) and CHCl<sub>3</sub>-Me<sub>2</sub>CO (5:1) as eluent to provide 1 (45 mg) and 3 (27 mg). Fraction 2.2 was subjected to Si gel via VLC with CHCl<sub>3</sub>-Me<sub>2</sub>CO (5:1) and CHCl<sub>3</sub>-PrOH (10:1-5:1) respectively to furnish 2 (7 mg), 4 (5 mg), and 5 (10 mg).

**Brachystemidine A (1):** white solid; mp 210–211.5 °C;  $[\alpha]_D^{28}$  laevo but unstable (*c* 0.24, MeOH); EIMS *m/z* 306 [M]<sup>+</sup> (18), 274 [M – OMe – H]<sup>+</sup> (4), 253 (12), 208 (7), 195 (16), 191 (45), 163 (24), 122 (15), 111 (14), 94 (100), 81 (77), 66 (20); <sup>1</sup>H NMR (DMSO-*d*<sub>6</sub>, 400 MHz) and <sup>13</sup>C NMR (DMSO-*d*<sub>6</sub>, 100.6 MHz) data, see Table 1; HREIMS *m/z* 306.1238 [M]<sup>+</sup> (calcd 306.1218).

**Brachystemidine B (2):** white solid; mp  $151-152 \,^{\circ}$ C;  $[\alpha]_D^{27}$ -3.1° (*c* 0.32, MeOH); EIMS *m/z* 306  $[M]^+$  (26), 274  $[M - OMe - H]^+$  (17), 207 (4), 195 (31), 192 (55), 191 (59), 181 (9), 180 (10), 163 (45), 135 (23), 122 (31), 111 (34), 94 (100), 81 (88), 71 (58), 66 (41); <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz) data, see Table 2; <sup>13</sup>C NMR (CDCl<sub>3</sub>, 100.6 MHz) data, see Table 3; HREIMS *m*/*z* 306.1226 [M]<sup>+</sup> (calcd 306.1216).

**Brachystemidine C (3):** colorless gum;  $[\alpha]_D{}^{21} - 21.0^{\circ}$  (*c* 0.25, CHCl<sub>3</sub>); EIMS *m*/*z* 322 [M]<sup>+</sup> (11), 290 (2), 211 (6), 192 (56), 191 (51), 119 (10), 111 (22), 94 (91), 93 (27), 82 (54), 81 (100), 66 (34); <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz) data, see Table 2; <sup>13</sup>C NMR (CDCl<sub>3</sub>, 100.6 MHz) data, see Table 3; HREIMS *m*/*z* 322.1176 [M]<sup>+</sup> (calcd 322.1165).

**Brachystemidine D (4):** colorless block; mp 147.5–149 °C;  $[\alpha]_D^{25}$  +3.52° (*c* 0.43, MeOH); EIMS *m*/*z* 292 [M]<sup>+</sup> (30), 274 [M – H<sub>2</sub>O]<sup>+</sup> (6), 192 (63), 191 (71), 182 (35), 181 (47), 163 (52), 135 (32), 111 (48), 94 (100), 81 (95), 66 (60); <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz) and <sup>13</sup>C NMR (CDCl<sub>3</sub>, 100.6 MHz) data, see Table 1; HREIMS *m*/*z* 292.1072 [M]<sup>+</sup> (calcd 292.1059).

**Brachystemidine E (5):** colorless gum;  $[\alpha]_D^{28} + 0.76^{\circ}$  (*c* 1.65, MeOH); EIMS *m*/*z* 308 [M]<sup>+</sup> (5), 290 [M - H<sub>2</sub>O]<sup>+</sup> (2), 192 (37), 191 (35), 111 (27), 101 (13), 94 (92), 82 (41), 81 (100), 66 (39); <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz) data, see Table 2; <sup>13</sup>C NMR (CDCl<sub>3</sub>, 100.6 MHz) data, see Table 3; HREIMS *m*/*z* 308.1022 [M]<sup>+</sup> (calcd 308.1008).

**Single-Crystal X-ray Analysis of 4.**<sup>4</sup> A crystal with the composition  $C_{14}H_{16}N_2O_5$  obtained from CHCl<sub>3</sub> was used for an X-ray structure determination. Data were acquired with a MAC DIP-2030K diffractometer, Mo K $\alpha$  radiation ( $\lambda$  0.71069 Å), graphite monochromator:  $M_t$  292.29 ( $C_{14}H_{16}N_2O_5$ ); crystal size 0.30 × 0.30 × 0.40 mm; monoclinic system, space group  $P2_1/c$ , 293 K; a = 6.5770(2) Å, b = 10.3520(5) Å, c = 20.5690-(9) Å, V = 1400.12 (10 Å<sup>3</sup>,  $D_c = 1.392$  g/cm<sup>3</sup>, Z = 4. The data were collected at 20 ± 1° by the  $\omega$ -2 $\theta$  scan technique to a maximum 2 $\theta$  value of 50.0°. A total of 2280 reflections were collected. The structure was solved by direct methods and expanded by the Fourier technique. The non-H atoms were refined anisotropically; H atoms were included but not refined.

**Acknowledgment.** The authors gratefully acknowledged the analytical group of the Kunming Institute of Botany, The Chinese Academy of Sciences, for recording all spectral data.

**Supporting Information Available:** This material is available free of charge via the Internet at http://pubs.acs.org.

## **References and Notes**

- Tang, C. L.; Ke, P.; Lu, D. Q.; Zhou, L. H.; Wu, C. Y. *Zhongguo Zhiwu Zhi*; Beijing Science Press: Beijing, 1996; Vol. 26, p 253.
   Wu, C. Y.; Zhou, T. Y.; Xiao, P. G. *A Compendium of New China*
- (2) Wu, C. Y.; Zhou, T. Y.; Xiao, P. G. A Compendium of New China Herbal Medicine; Shanghai Science and Technology Press: Shanghai, 1990; Vol. 3, p 43.
- 1990; Vol. 3, p 43.
  (3) Reinecke, M. G.; Zhao, Y. Y. *J. Nat. Prod.* **1988**, *51*, 1236–1240.
  (4) Crystallographic data for compound **4** has been deposited with the
- (4) Crystantographic data for compound 4 has been deposited with the Cambridge Crystallographic Data Center as deposition No. CCDC 163685. Copies of the data can be obtained, free of charge, on application to the CCDC, 12 Union Road, Cambridge CB2 IEZ UK (fax: + 44-(0)1223-336033; e-mail: deposit@ccdc.cam.ac.uk).

NP010330C